Last edition
News about "Merck Research Laboratories"
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Merck Research Laboratories | 26/06/2026 | By News Bureau | 179
US FDA Approves KEYTRUDA-WELIREG Combination for Adjuvant ccRCC
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for the adjuvant treatment of certain patients with clear cell Renal Cell Carcinoma (ccRCC). The approval expands treatment options for kidney cancer patients at high risk of recurrence following surgery.
Merck Research Laboratories | 15/06/2026 | By News Bureau
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Merck Research Laboratories | 22/01/2026 | By News Bureau | 138
KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC
KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.
Merck Research Laboratories | 18/12/2025 | By News Bureau | 177
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Merck Research Laboratories | 29/10/2025 | By Dineshwori | 331
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Merck Research Laboratories | 13/10/2025 | By Dineshwori | 301
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Merck Research Laboratories | 07/10/2025 | By Dineshwori | 544
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy